Insider Trading Alert - CNCE, UVE And EBSB Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 10, 2015, 92 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $6.99 to $188,811,000.00.

Highlighted Stocks Traded by Insiders:

Concert Pharmaceuticals (CNCE) - FREE Research Report

Silverman Robert, who is Senior VP, General Counsel at Concert Pharmaceuticals, sold 5,000 shares at $16.35 on June 10, 2015. Following this transaction, the Senior VP, General Counsel owned 15,000 shares meaning that the stake was reduced by 25% with the 5,000-share transaction.

The shares most recently traded at $16.39, up $0.04, or 0.23% since the insider transaction.

The average volume for Concert Pharmaceuticals has been 312,900 shares per day over the past 30 days. Concert Pharmaceuticals has a market cap of $347.1 million and is part of the health care sector and drugs industry. Shares are up 21.32% year-to-date as of the close of trading on Wednesday.

Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drugs for central nervous system disorders, genetic diseases, renal disease, inflammatory disease, and cancer. Currently, there are 3 analysts who rate Concert Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CNCE - FREE

TheStreet Quant Ratings rates Concert Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full Concert Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Universal Insurance Holdings (UVE) - FREE Research Report

Pietrangelo Michael, who is Director at Universal Insurance Holdings, sold 32,000 shares at $25.37 on June 10, 2015. Following this transaction, the Director owned 59,248 shares meaning that the stake was reduced by 35.07% with the 32,000-share transaction.

Springer Jon, who is EVP and COO at Universal Insurance Holdings, sold 6,000 shares at $25.49 on June 10, 2015. Following this transaction, the EVP and COO owned 401,279 shares meaning that the stake was reduced by 1.47% with the 6,000-share transaction.

The shares most recently traded at $24.56, down $0.93, or 3.79% since the insider transaction. Historical insider transactions for Universal Insurance Holdings go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 35,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 171,342
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 313,570

The average volume for Universal Insurance Holdings has been 322,200 shares per day over the past 30 days. Universal Insurance Holdings has a market cap of $882.2 million and is part of the financial sector and insurance industry. Shares are up 20.29% year-to-date as of the close of trading on Wednesday.

Universal Insurance Holdings, Inc., through its subsidiaries, provides various property and casualty insurance products. The company primarily underwrites homeowners' insurance products; and offers reinsurance intermediary brokerage services. The stock currently has a dividend yield of 1.95%. The company has a P/E ratio of 10.6. Currently, there are no analysts who rate Universal Insurance Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on UVE - FREE

TheStreet Quant Ratings rates Universal Insurance Holdings as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Universal Insurance Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Meridian Bancorp (EBSB) - FREE Research Report

Gunning Thomas J, who is Director at Meridian Bancorp, bought 305 shares at $12.80 on June 10, 2015. Following this transaction, the Director owned 15,348 shares meaning that the stake was boosted by 2.03% with the 305-share transaction.

The shares most recently traded at $13.00, up $0.20, or 1.55% since the insider transaction. Historical insider transactions for Meridian Bancorp go as follows:

  • 4-Week # shares sold: 1,224
  • 12-Week # shares sold: 1,224
  • 24-Week # shares sold: 6,224

The average volume for Meridian Bancorp has been 167,600 shares per day over the past 30 days. Meridian Bancorp has a market cap of $702.8 million and is part of the financial sector and banking industry. Shares are up 16.58% year-to-date as of the close of trading on Wednesday.

Meridian Bancorp, Inc. operates as a holding company for East Boston Savings Bank that provides financial services to individuals and businesses primarily in Suffolk, Middlesex, and Essex Counties, Massachusetts. The company has a P/E ratio of 27.8. Currently, there are no analysts who rate Meridian Bancorp a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EBSB - FREE

TheStreet Quant Ratings rates Meridian Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, impressive record of earnings per share growth, compelling growth in net income and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Meridian Bancorp Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet